PET/MR in recurrent glioblastoma patients treated with regorafenib: [


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
01 Jan 2022
Historique:
pubmed: 12 11 2021
medline: 24 12 2021
entrez: 11 11 2021
Statut: ppublish

Résumé

The use of regorafenib in recurrent glioblastoma patients has been recently approved by the Italian Medicines Agency (AIFA) and added to the National Comprehensive Cancer Network (NCCN) 2020 guidelines as a preferred regimen. Given its complex effects at the molecular level, the most appropriate imaging tools to assess early response to treatment is still a matter of debate. Diffusion-weighted imaging and O-(2- We retrospectively reviewed 16 consecutive GBM patients who underwent [ Percentage difference in FET volumes correlates with the corresponding percentage difference in ADC ( In recurrent glioblastoma patients treated with regorafenib, [ Simultaneous evaluation of [

Identifiants

pubmed: 34762492
doi: 10.1259/bjr.20211018
pmc: PMC8722234
doi:

Substances chimiques

Antineoplastic Agents 0
Phenylurea Compounds 0
Pyridines 0
Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
regorafenib 24T2A1DOYB

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

20211018

Références

J Nucl Med. 2011 Jun;52(6):856-64
pubmed: 21622893
J Neurooncol. 2010 Feb;96(3):423-31
pubmed: 19859666
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
Neoplasia. 2009 Feb;11(2):102-25
pubmed: 19186405
J Clin Med. 2019 Nov 21;8(12):
pubmed: 31766326
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2377-2386
pubmed: 29982845
Front Neurol. 2015 Feb 23;6:33
pubmed: 25755649
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):540-557
pubmed: 30519867
Int J Cancer. 2011 Jul 1;129(1):245-55
pubmed: 21170960
J Magn Reson Imaging. 2010 Mar;31(3):538-48
pubmed: 20187195
Radiology. 2009 Jul;252(1):182-9
pubmed: 19561256
Mol Cancer Ther. 2013 Jul;12(7):1322-31
pubmed: 23619301
Neuro Oncol. 2018 Feb 19;20(3):295-298
pubmed: 29471448
Neurooncol Adv. 2019 Oct 20;1(1):vdz038
pubmed: 32642667
Brain. 2005 Mar;128(Pt 3):678-87
pubmed: 15689365
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):591-602
pubmed: 30327856
Radiology. 2004 Aug;232(2):451-60
pubmed: 15215555
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
Lancet Oncol. 2019 Jan;20(1):110-119
pubmed: 30522967
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1455-60
pubmed: 15956515
Neuro Oncol. 2014 Dec;16(12):1599-606
pubmed: 25059209
J Neuroradiol. 2018 Jul;45(4):236-241
pubmed: 29274693
J Neuroradiol. 2019 Feb;46(1):36-43
pubmed: 29733920
EJNMMI Res. 2017 Dec;7(1):48
pubmed: 28560582
Neuro Oncol. 2012 Sep;14(9):1178-84
pubmed: 22869622
World Neurosurg. 2019 Feb;122:e812-e820
pubmed: 30391622
Neuroradiol J. 2019 Aug;32(4):241-249
pubmed: 31066622
Neuro Oncol. 2014 Oct;16 Suppl 7:vii36-47
pubmed: 25313237
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
pubmed: 11121466
AJNR Am J Neuroradiol. 2011 May;32(5):882-9
pubmed: 21330401
J Magn Reson Imaging. 1999 Jan;9(1):53-60
pubmed: 10030650
Magn Reson Imaging. 2006 Nov;24(9):1131-42
pubmed: 17071335
Clin Transl Oncol. 2018 Aug;20(8):939-953
pubmed: 29218626
AJNR Am J Neuroradiol. 2012 Oct;33(9):1763-70
pubmed: 22538078
Nat Rev Neurol. 2017 May;13(5):279-289
pubmed: 28387340
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1458-1467
pubmed: 31919633
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):22-33
pubmed: 23053325
CNS Oncol. 2019 Mar 1;8(1):CNS28
pubmed: 30806082
J Neurooncol. 2012 Jul;108(3):491-8
pubmed: 22426926
J Nucl Med. 2017 May;58(5):700-705
pubmed: 28153956
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
J Neurosurg. 2005 Sep;103(3):428-38
pubmed: 16235673
Radiology. 2005 Jun;235(3):985-91
pubmed: 15833979
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
AJR Am J Roentgenol. 2017 Jan;208(1):57-65
pubmed: 27726412

Auteurs

Giuseppe Lombardi (G)

Department of Oncology, Oncology 1, Veneto Institute of Oncology - IRCCS, Padua, Italy.

Alessandro Spimpolo (A)

Nuclear Medicine Unit, Department of Medicine - DIMED, Padua University Hospital, Padua, Italy.

Sara Berti (S)

Nuclear Medicine Unit, Department of Medicine - DIMED, Padua University Hospital, Padua, Italy.

Cristina Campi (C)

Department of Mathematics, University of Genoa, Genoa, Italy.

Maria Giulia Anglani (MG)

Neuroradiology Unit, Azienda Ospedaliera di Padova, Padua, Italy.

Rossella Simeone (R)

Nuclear Medicine Unit, Department of Medicine - DIMED, Padua University Hospital, Padua, Italy.

Laura Evangelista (L)

Nuclear Medicine Unit, Department of Medicine - DIMED, Padua University Hospital, Padua, Italy.

Francesco Causin (F)

Neuroradiology Unit, Azienda Ospedaliera di Padova, Padua, Italy.

Giovanni Zorzi (G)

Department of Neurosciences (DNS), University of Padua, Padua, Italy.

Giancarlo Gorgoni (G)

Radiopharmacy, Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.

Mario Caccese (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology - IRCCS, Padua, Italy.

Marta Padovan (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology - IRCCS, Padua, Italy.

Vittorina Zagonel (V)

Department of Oncology, Oncology 1, Veneto Institute of Oncology - IRCCS, Padua, Italy.

Diego Cecchin (D)

Nuclear Medicine Unit, Department of Medicine - DIMED, Padua University Hospital, Padua, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH